AGENUS INC (AGEN): restructuring charge — Agenus cuts workforce 25%, pauses non-core programs to focus on BOT/BAL

AGENUS INC

Workforce reduction of ~25% expected to save $2.8M by year-end; severance cost ~$1.4M.
Total savings of ~$40M by end of 2023 from halting non-BOT/BAL preclinical and clinical programs.
Partner-funded programs unaffected; first BOT/BAL regulatory filing targeted in 2024.
Restructuring supports sped-up registration and commercialization of lead immunotherapy.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

AGENUS INC announced a restructuring with charges of approximately $1.4 million affecting Agenus Inc. (excluding its independently operating subsidiaries) (approximately 25%).

Type: restructuring
Charge: approximately $1.4 million
Affected area: Agenus Inc. (excluding its independently operating subsidiaries)
Headcount: approximately 25%

Exact text from the filing

As part of this effort, Agenus Inc. (excluding its independently operating subsidiaries) is reducing its workforce by approximately 25%, which the company expects to result in savings of approximately $2.8 million by year-end, after accounting for the cost of the workforce reduction of approximately $1.4 million.

View on SEC.gov

13 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

AGENUS INC filing history →

Source: SEC EDGAR

accession 0001157523-23-001357

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.